Overview of DHR

What is DHR? Definition and Identity

Property	Description
Active Ingredient	Levomenthol and Methyl Salicylate
Form	Topical Solution, Liniment, or Rub
Pharmacological Class	Topical Counterirritant and Local Analgesic
General Purpose	Provides temporary, localized symptomatic relief
Origin	Combined product; components are naturally derived and/or synthetic

DHR is fundamentally a combined topical preparation classified as a Topical Counterirritant and Local Analgesic. It is an external product designed exclusively for topical application to the skin. This classification signifies that the medicinal effect of DHR is strictly localized, focusing on providing symptomatic relief directly where it's applied, rather than systemic action. Products containing combinations of levomenthol and methyl salicylate are recognized as authorized over-the-counter external analgesics. This confirms the preparation's clinically recognized classification for temporary external relief.

Composition: Active Ingredients and Form

The identity of DHR is defined by its two principal active ingredients: Levomenthol and Methyl Salicylate. DHR is a combination product because it leverages both of these substances for a dual sensory and pharmacological effect. Levomenthol, the component responsible for the characteristic immediate cooling sensation, is the active isomer of menthol often derived from mint species. Methyl Salicylate, which is metabolized into salicylic acid after absorption, functions as a rubefacient (warming agent) and provides localized analgesic activity.

These components are typically formulated into a liniment or topical solution, suspended in an alcoholic or oily base to facilitate application and skin contact. The utility of Methyl Salicylate for localized soothing is supported by various pharmacological monographs recognizing its mechanism in topical preparations. The overall purpose of DHR is to afford temporary comfort by stimulating peripheral sensory nerves, thereby providing focused, site-specific relief for common issues such as muscular stiffness, through a non-systemic approach.

What side effects are possible with DHR?

Possible Side Effects and Safety Information

Dihydroergotamine (DHR) is associated with an established safety profile defined by both frequently reported, generally milder reactions and potential for serious systemic events, as documented by regulatory authorities.

Adverse Reactions and Frequencies

Side effects are categorized based on incidence rates observed in clinical use. Common side effects (1% to 10% incidence) include nausea, vomiting, diarrhea, and generalized stiffness. For the nasal spray formulation, rhinitis and local irritation at the site of administration are often classified as Very Common (ge 10%). Less common effects include insomnia and dry mouth. The regulatory labeling classifies reactions affecting the gastrointestinal system and the nervous system as primary categories.

Serious Adverse Reactions and Restrictions

Regulatory documentation highlights the potential for serious adverse reactions related to vasoconstriction. These include vasospasm, which may lead to cerebral ischemia (stroke) or myocardial ischemia and myocardial infarction (heart attack). Rare, serious fibrotic complications, such as retroperitoneal fibrosis, have been reported following prolonged daily use of the injectable form.

Due to these risks, DHR is contraindicated in patients with pre-existing vascular conditions, including uncontrolled hypertension and ischemic heart disease. It is also contraindicated in severe renal impairment and severe hepatic impairment, as well as during pregnancy due to its oxytocic properties. Concomitant use with strong CYP3A4 inhibitors is also prohibited, as this significantly increases the risk of severe vasospasm.

Overdose and Emergency Response

Overdose and when to seek help

Element	Regulatory Statement/Manifestation
Documented Overdose Manifestations	Overdose, typically resulting from accidental oral ingestion or extensive topical application, presents with signs of Systemic Salicylate Toxicity (Salicylism). Symptoms include nausea, vomiting, and tinnitus (ringing in the ears). Severe toxicity is documented to affect the Central Nervous System, manifesting as seizures, confusion, or loss of consciousness.
Life-Threatening Outcomes	The official prescribing information notes the potential for life-threatening outcomes, including respiratory depression, cardiovascular collapse, and organ failure following severe exposure.
Emergency-Response Requirements	Individuals must seek immediate medical attention and contact a poison control center or emergency services immediately for any suspected overdose, especially if passing out or trouble breathing occurs.
Supportive Management	Treatment is symptomatic and supportive, as no specific antidote is known. Management may include gastric lavage for ingestion, administration of activated charcoal, and continuous monitoring of vital signs and diagnostic testing.

Population-Specific Overdose Note: Use in pediatrics and teenagers with certain underlying viral illnesses is associated with a risk of Reye's syndrome, a documented population-specific concern.

Connection to the overall overdose profile: The DHR overdose profile is defined by the severe systemic risk from salicylate absorption. Regulatory documents mandate that immediate medical help must be sought for the onset of serious systemic or CNS symptoms due to the potential for life-threatening events such as organ failure or respiratory depression. Management is described as symptomatic and supportive, based on the documented constraint that no specific antidote is known for this overdose scenario.

Therapeutic Uses of DHR

What DHR Treats: Acute Symptom Management

Dihydroergotamine (DHE) is applied across therapeutic domains for the acute management of specific, intense symptom clusters related to headache. The primary therapeutic application for DHE is commonly used across conditions presenting with acute episodes of migraine headaches and cluster headache episodes.

DHE may be part of symptomatic management in situations where patients experience acute or disruptive episodes linked to migraine headaches, and it is considered relevant for easing symptoms associated with acute episodes of cluster headaches. This supportive management assists with maintaining functional stability and helps ease the overall symptom load. DHE is applied in clinical settings that involve acute or unstable symptom patterns.

The medication is commonly used to help with symptoms related to: migraine headaches (with or without aura) and acute cluster headache episodes.

This assistance contributes to improved comfort during these periods of heightened symptoms and supports patients during difficult episodes by easing distress.

“DHE is applied when appropriate for managing symptoms that interfere with daily comfort during acute headache episodes.”

Quick Fact: Is commonly used to help with Symptoms related to heightened physiological activity

Eligibility and Restrictions for Use

Official Eligibility for DHR (Dihydroergotamine Mesylate)

DHR is indicated for the acute treatment of migraine headaches (with or without aura) and cluster headache episodes in adults only. Regulatory documents establish clear exclusions based on absolute contraindications.

Contraindicated Populations (Must Not Use):

Cardiovascular Status: Patients with ischemic heart disease, coronary artery vasospasm, peripheral arterial disease, or uncontrolled hypertension.
Organ Function: Individuals with severe hepatic (liver) or severe renal (kidney) impairment, and those with sepsis.
Specific Conditions: Patients with hemiplegic or basilar migraine, or known hypersensitivity to ergot alkaloids.

Restrictions and Limitations:

Age: Safety and effectiveness have not been established for pediatric patients under 18 years of age.
Physiological Status: Use is contraindicated during pregnancy and is not recommended for nursing mothers.
Concomitant Use: The medicine is strictly contraindicated with strong CYP3A4 inhibitors and must not be used within 24 hours of taking other 5-HT1 agonists (triptans) or ergot-type medications.
Conditional Use: Older adults or patients with risk factors for coronary artery disease require a pre-treatment cardiovascular evaluation.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The interaction profile for Dihydroergotamine (DHR) is defined by its metabolism and its intrinsic vascular activity, as documented in official government labeling. The primary concern is elevated drug exposure and the risk of heightened vasoconstriction.

Documented Pharmacokinetic Interactions

DHR is metabolized by the Cytochrome P450 3A4 (CYP3A4) enzyme system. Co-administration with Potent CYP3A4 Inhibitors is strictly restricted, as these agents reduce the clearance of DHR, which can result in dangerously increased plasma concentrations. Substances classified as potent inhibitors include specific azole antifungals (e.g., Ketoconazole), certain macrolide antibiotics (e.g., Clarithromycin), and most protease inhibitors.

Pharmacodynamic and Timing Constraints

The co-administration of DHR with other substances that possess vasoconstrictive properties is prohibited due to the risk of additive effects and prolonged vasospasm. This includes other Ergot-Type Medications and all 5-HT1 Receptor Agonists (Triptans). A mandatory timing rule requires that DHR must not be administered within 24 hours of the use of a Triptan or any other ergot alkaloid.

Other Interaction Considerations

The interaction risk with CYP3A4 inhibitors is noted to be intensified in patients with severe hepatic impairment due to already compromised metabolic function. Furthermore, the official prescribing information includes warnings against the concurrent use of strong CYP3A4 inhibitors and advises caution with substances such as Grapefruit Juice, which may also affect the CYP3A4 pathway.

Mechanism of Action

How DHR Works

The mechanism involves two complementary peripheral actions: the modulation of sensory signaling and the localized inhibition of eicosanoid synthesis.

Peripheral Sensory Signal Modulation (Counter-Irritation)

Levomenthol initiates its effect through the agonism of the Transient Receptor Potential Melastamin 8 (TRPM8) ion channel, a receptor on peripheral nerve endings that senses cold. The resulting, intense afferent signaling from TRPM8 activation generates a competing sensory input, leading to functional override (counter-irritation) of other nociceptive signaling in the area. This engagement modulates peripheral sensory input, initiating the primary physiological response.

Localized Eicosanoid Pathway Inhibition

The complementary effect is mediated by Methyl Salicylate, a pro-drug that is hydrolyzed in the skin to salicylic acid. Salicylic acid acts as an inhibitor of Cyclooxygenase (COX) enzymes, suppressing the local synthesis of pro-inflammatory prostaglandins. This localized biochemical action reduces the synthesis of pro-inflammatory prostaglandins. This effect contributes to the local modulation of the eicosanoid cascade exclusively in the treated area. The combination utilizes both neural modulation and biochemical mediator suppression, which results in a dual-mechanism physiological response.

Dosage and Administration Information

Instruction Map: How to use DHR — Official Administration Guidelines

The administration of Dihydroergotamine Mesylate (DHR) is strictly governed by protocols designed for acute intervention, with usage and limits defined in official documentation.

Administration Scope

Field	Official Specification
Route of administration	Intravenous (IV), Intramuscular (IM), or Subcutaneous (SC) injection.
Dosing schedule	Initial dose is 1 mg via IM or SC injection, or 0.5 mg via the IV route.
Special procedural conditions	The total cumulative dose must not exceed 3 mg for IM/SC use or 2 mg for IV use per acute episode.
Age-group rules	Specific dose adjustments for general use in older adults or minor hepatic/renal impairment are not detailed in general instructions.

Instruction Classifications (High-Level)

Classification	Specification
Administration method type	Parenteral (Injection).
Frequency pattern	As-needed (PRN) for acute episodes.
Use-context constraints	Must not be administered on a daily basis for prolonged periods. Total use is restricted to a maximum of 6 mg within any 7-day period.

Resulting Procedural Structure

Official step sequence:

Initial Dosing: The medicine is administered at the specified initial dose based on the chosen injection route (IM, SC, or IV).
Dose Repetition: If required, the dose may be repeated after a minimum interval of 60 minutes.
Limit Adherence: Administration must be discontinued upon reaching the maximum dose limit for the episode or the maximum limit for the 7-day period.

Connection to the overall use protocol (3 sentences): The official instructions establish DHR as a strictly acute-use medicine administered solely by injection methods. These regulations enforce precise limits on dose repetition and total dose accumulation per episode and per week to constrain the overall frequency of administration. This structured schedule of initial dosing and subsequent time-based limits is the mandatory framework for its proper use.

Recent Clinical Evidence

Evidence for Musculoskeletal Symptoms

Research on DHR (Levomenthol and Methyl Salicylate) focuses primarily on its study context: symptoms related to acute, mild to moderate muscle strain and minor musculoskeletal discomfort. The core evidence relies on controlled clinical trials, specifically Randomized Controlled Trials (RCTs), where the topical solution is compared against an inactive placebo base. The regulatory status of the active combination, as recognized in the FDA's Over-the-Counter (OTC) Monograph, is based on evidence suggesting the product is generally recognized for use in the temporary management of symptoms related to minor aches and strains. Researchers monitored changes in how patients reported their pain, recording differences in pain intensity scores between the active solution and the placebo. Research has also explored temporary physiological changes by assessing markers like localized cutaneous blood flow.

Study Design and Follow-up

The design of the primary research centers on measuring temporary and episodic changes in discomfort. Key endpoints measured include changes in pain intensity scores (such as the VAS) and the Summed Pain Intensity Difference (SPID) tracked over defined periods. The measurements in the studies were often observed only over short intervals, typically spanning 8 to 12 hours after a single dose. This short-term focus means the research does not provide insight into outcomes related to chronic or recurring conditions.

Evidence in Special Populations and Limitations

The core research was observed in primarily adult patients with mild to moderate acute strain. For certain groups, such as children (typically those under 12 years of age), data for certain groups remain insufficient. Long-term effects are not fully established, as the existing research focuses on acute, single-dose responses. There is limited information for long-term outcomes or the consequences of repeated use over extended periods. Furthermore, comparative evidence against other pharmacological categories is not widely published. Researchers have noted a relative lack of comprehensive, published clinical data in peer-reviewed literature compared to the product’s long history and widespread use.

Frequently Asked Questions (FAQ)

Common questions about DHR (FAQ)

Q: Does DHR need to be taken at the exact same time every day?

According to official regulations, DHR is intended for as-needed (PRN) use during acute episodes, following strict dosing limits. Regulatory documents indicate that the medicine is not designed to be administered on a chronic, daily basis for prolonged periods.

Q: If I miss a dose of DHR, what should I generally do?

If a required dose is delayed, official instructions permit a repeat dose after a minimum waiting period of 60 minutes. Official guidelines emphasize that the maximum dose limits for both the acute episode and the 7-day period must be maintained.

Q: What happens if I accidentally take too much DHR?

Official information on potential overdose describes serious symptoms like visual disturbances (e.g., blurred vision), confusion, dizziness, fainting, and the severe side effects of too much vasoconstriction, such as numbness and tingling. Official information states that emergency medical help should be contacted immediately if an overdose is suspected.

Q: What are the possible interactions with over-the-counter pain relievers?

The official label does not specifically list common over-the-counter pain relievers (like ibuprofen or acetaminophen). However, warnings are in place against combining DHR with other substances that cause vasoconstriction (narrowing of blood vessels) and advise caution with agents that may interfere with the way DHR is processed by the body.

Q: What are the general expectations for a patient starting DHR?

DHR is authorized for acute treatment. Official information indicates that effects and common reactions, such as nausea and vomiting, may be observed shortly after administration. These common reactions often include effects on the gastrointestinal system and general stiffness.

Q: Can DHR cause tiredness or drowsiness?

Drowsiness is not typically listed as a common side effect in the official regulatory labeling. However, official patient information indicates that the medicine may affect coordination, reaction time, or judgment, due to reactions affecting the nervous system.

Q: Why is DHR not recommended for children?

The safety and effectiveness of DHR have not been established for pediatric patients, defined as those under 18 years of age. Therefore, based on official regulatory documents, it is not indicated for use in this population.

Q: What should I know about DHR and surgery?

Official patient information indicates that patients should inform their healthcare provider or dentist about DHR use if they are having surgery, including dental procedures. This precaution is advised due to the potential for serious adverse reactions related to the medicine's effects on blood circulation.

Q: Are there any reported interactions between DHR and alcohol?

Official patient information indicates that alcohol consumption while using DHR may be associated with an increased risk of side effects such as dizziness or fainting spells.

Q: Is DHR a strong medicine or a milder one?

DHR is an ergot alkaloid and is classified as a prescription medicine for the acute treatment of severe symptoms. Due to the potential for serious adverse events like vasospasm (spasm of blood vessels) and heart issues, its use is strictly controlled and prohibited in patients with pre-existing vascular conditions.

Q: Are there any common foods or drinks that should be avoided with DHR?

Official warnings advise caution regarding foods and drinks that may affect the CYP3A4 pathway, which processes the medicine in the body. Specifically, the consumption of grapefruit juice should be limited as it may increase the level of DHR in the blood.

Q: Can DHR be taken long-term, based on research?

Regulatory documents indicate that DHR is not intended for chronic use. The documents warn against administering it on a chronic daily basis due to the risk of rare, serious complications, and the potential for a condition known as medication-overuse headache.

Q: Is DHR considered addictive or habit-forming?

DHR is classified by the Drug Enforcement Administration (DEA) as Not a controlled medication. It is not considered an opioid or a scheduled substance.

Q: What happens if DHR is stopped suddenly?

Regulatory documents indicate that the medicine is not intended for chronic daily use, so there are no official instructions regarding sudden cessation after acute use. However, discontinuing use after frequent or prolonged administration may be necessary to avoid a condition known as medication-overuse headache.

Q: Is DHR suitable for older adults?

The official label notes that older adults, or those with risk factors for coronary artery disease, require a pre-treatment cardiovascular evaluation before using DHR. The official documentation indicates that specific general dose adjustments are not detailed in the general instructions.

Q: Are there different versions or brands of DHR available?

DHR is available in multiple formulations, including various injectable forms (IV, IM, SC) and a nasal spray. Lower-cost generic versions are available for some of these formulations.

Q: How is DHR different from similar medicines used for the same purpose?

DHR is classified as an ergot alkaloid and a 5-HT1D receptor agonist. Official documents include a warning against using DHR within 24 hours of taking a triptan (5-HT1 receptor agonist) or other ergot-type medication.

Q: Does DHR require any special monitoring by a healthcare provider?

Official warnings indicate that a healthcare provider may monitor the patient’s progress closely while they are receiving DHR. Blood tests and a cardiovascular evaluation may be needed for certain patients to check for possible unwanted effects.

Q: Can I drive or operate machinery while taking DHR?

Official patient information advises against driving or operating machinery until the patient knows how the medicine affects them, as it may affect coordination, reaction time, or judgment.

Q: Can DHR affect mood or cause mood swings?

The official regulatory label lists insomnia (difficulty sleeping) as a less common side effect in the nervous system category. Specific psychiatric changes or mood swings are not listed as common or serious adverse reactions in the main labeling sections.

Q: Are generic versions of DHR available, and are they the same?

Lower-cost generic versions of DHR are available. Generic drug products are approved by the FDA if they are demonstrated to be bioequivalent, meaning they work the same way in the body as the original reference drug.

Q: What is the average time DHR stays in the system?

Official pharmacokinetic information indicates that the drug is eliminated from the body in multiple stages, with a terminal half-life of about 9 hours. The major way the drug is removed is primarily via bile through the feces.

Q: What is the difference between DHR and a supplement for the same condition?

DHR is a prescription medicine that is approved by the FDA for the acute treatment of specific headache conditions, having undergone rigorous testing for safety and efficacy. Dietary supplements are products that are not regulated as drugs and do not undergo the same stringent regulatory approval process.

Q: Is it possible for DHR to stop working after a while?

Official warnings note that using migraine medications, including DHR, too often (defined as 10 or more days a month) can potentially worsen the frequency of headaches. This condition is called medication-overuse headache (MOH).

Q: Is it typical for DHR to cause headaches?

The official label warns that taking DHR for 10 or more days per month can actually worsen migraines, causing a condition known as medication-overuse headache. DHR is not indicated for treating general headaches, but for acute, specified types.

Q: What kind of side effects are considered minor with DHR?

Common side effects (occurring in 1% to 10% of patients) are generally considered milder than the serious risks associated with vasoconstriction. These common reactions include nausea, vomiting, diarrhea, and generalized stiffness, along with less common effects such as insomnia and dry mouth.

Q: Is DHR a controlled substance?

DHR is classified by the Drug Enforcement Administration (DEA) as Not a controlled medication.

How should DHR be stored and disposed of?

Dihydroergotamine (DHE) must be stored under specific conditions to maintain product integrity and ensure safe use.

Storage Domain	Official Regulatory Requirement
Temperature & Protection	Store at Controlled Room Temperature (20 C to 25 C). Do not refrigerate or freeze. Protect from light, moisture, and excess heat.
Container & Stability	Keep in the original container, tightly closed, and out of sight and reach of children. The DHE injection must be discarded 1 hour after opening; the nasal spray must be discarded 8 hours after assembly.
Disposal Requirements	Used needles and syringes must be immediately placed in an FDA-cleared, puncture-resistant sharps container. Unused or expired medication should be disposed of through a drug take-back program or according to local regulations, as the product is classified as a hazardous drug.

DHR

DHR

Medically reviewed